Iowa’s Medical Cannabidiol Board will consider changes to the state’s limited medicinal cannabis program on Friday, including petitions to add new medical conditions that qualify patients to participate in it. The board will also consider a proposal to replace a 3% limit on THC in medical marijuana products with a purchase limit on the high-inducing cannabinoid.
During its last meeting of the year on Friday, the board is expected to vote on adding post-traumatic stress disorder (PTSD), opioid use disorder, Alzheimer’s disease, and intellectual disability with aggression and/or self-injury as qualifying conditions for the state’s medical CBD program. Currently, the program is only open to patients with chronic pain, seizures, Crohn’s disease, multiple sclerosis, HIV/AIDS, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, cancer with specified symptoms, and terminal diseases with a projected life expectancy of less than one year.
The petitions to add PTSD, Alzheimer’s disease, and opioid abuse disorder were submitted by one of the state’s two authorized medical cannabis producers, MedPharm Iowa. Lucas Nelson, the general manager of MedPharm Iowa, said that the petition to add PTSD cited more than 60 sources that demonstrate the efficacy of medical marijuana for treating people with the condition, making it one of